Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Receivables: 2022-2025

Historic Receivables for Fennec Pharmaceuticals (FENC) over the last 3 years, with Sep 2025 value amounting to $19.3 million.

  • Fennec Pharmaceuticals' Receivables rose 49.85% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.2 million, marking a year-over-year increase of 47.10%. This contributed to the annual value of $12.9 million for FY2024, which is 46.18% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Receivables of $19.3 million as of Q3 2025, which was up 10.52% from $17.5 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Receivables peaked at $19.3 million during Q3 2025, and registered a low of $1.5 million during Q4 2022.
  • Its 3-year average for Receivables is $10.7 million, with a median of $12.3 million in 2024.
  • Data for Fennec Pharmaceuticals' Receivables shows a peak YoY spiked of 510.46% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Fennec Pharmaceuticals' Receivables stood at $1.5 million in 2022, then skyrocketed by 470.49% to $8.8 million in 2023, then surged by 46.18% to $12.9 million in 2024, then spiked by 49.85% to $19.3 million in 2025.
  • Its Receivables stands at $19.3 million for Q3 2025, versus $17.5 million for Q2 2025 and $15.4 million for Q1 2025.